These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 27371605)

  • 1. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the Genome-Editing Toolbox with
    Nakamura A; Yamamoto H; Yano T; Hasegawa R; Makino Y; Mitsuda N; Terakawa T; Ito S; Sugano SS
    CRISPR J; 2024 Aug; 7(4):197-209. PubMed ID: 39111827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing.
    Kelley ML; Strezoska Ž; He K; Vermeulen A; Smith Av
    J Biotechnol; 2016 Sep; 233():74-83. PubMed ID: 27374403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of CRISPR-SpyCas9 inhibition by an anti-CRISPR protein.
    Dong D; Guo M; Wang S; Zhu Y; Wang S; Xiong Z; Yang J; Xu Z; Huang Z
    Nature; 2017 Jun; 546(7658):436-439. PubMed ID: 28448066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A catalogue of biochemically diverse CRISPR-Cas9 orthologs.
    Gasiunas G; Young JK; Karvelis T; Kazlauskas D; Urbaitis T; Jasnauskaite M; Grusyte MM; Paulraj S; Wang PH; Hou Z; Dooley SK; Cigan M; Alarcon C; Chilcoat ND; Bigelyte G; Curcuru JL; Mabuchi M; Sun Z; Fuchs RT; Schildkraut E; Weigele PR; Jack WE; Robb GB; Venclovas Č; Siksnys V
    Nat Commun; 2020 Nov; 11(1):5512. PubMed ID: 33139742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthogonal CRISPR-Cas tools for genome editing, inhibition, and CRISPR recording in zebrafish embryos.
    Takasugi PR; Wang S; Truong KT; Drage EP; Kanishka SN; Higbee MA; Bamidele N; Ojelabi O; Sontheimer EJ; Gagnon JA
    Genetics; 2022 Jan; 220(1):. PubMed ID: 34735006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1.
    Kweon J; Jang AH; Kim DE; Yang JW; Yoon M; Rim Shin H; Kim JS; Kim Y
    Nat Commun; 2017 Nov; 8(1):1723. PubMed ID: 29167440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The initiation, propagation and dynamics of CRISPR-SpyCas9 R-loop complex.
    Zeng Y; Cui Y; Zhang Y; Zhang Y; Liang M; Chen H; Lan J; Song G; Lou J
    Nucleic Acids Res; 2018 Jan; 46(1):350-361. PubMed ID: 29145633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
    Haeussler M; Concordet JP
    J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9.
    Barkau CL; O'Reilly D; Rohilla KJ; Damha MJ; Gagnon KT
    Nucleic Acid Ther; 2019 Jun; 29(3):136-147. PubMed ID: 30990769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the mechanisms of PAMless DNA interrogation by SpRY-Cas9.
    Hibshman GN; Bravo JPK; Hooper MM; Dangerfield TL; Zhang H; Finkelstein IJ; Johnson KA; Taylor DW
    Nat Commun; 2024 Apr; 15(1):3663. PubMed ID: 38688943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.
    Fonfara I; Le Rhun A; Chylinski K; Makarova KS; Lécrivain AL; Bzdrenga J; Koonin EV; Charpentier E
    Nucleic Acids Res; 2014 Feb; 42(4):2577-90. PubMed ID: 24270795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit.
    Murugan K; Babu K; Sundaresan R; Rajan R; Sashital DG
    Mol Cell; 2017 Oct; 68(1):15-25. PubMed ID: 28985502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome Editing in Zebrafish by ScCas9 Recognizing NNG PAM.
    Liu Y; Liang F; Dong Z; Li S; Ye J; Qin W
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.